Trials / Completed
CompletedNCT00101608
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium. The safety of this treatment will also be studied.
Conditions
- Transitional Cell Carcinoma
- Bladder Neoplasms
- Kidney Neoplasms
- Ureter Neoplasms
- Bladder Cancer
- Neoplasm, Bladder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vinflunine | solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2005-01-13
- Last updated
- 2010-03-02
Locations
75 sites across 15 countries: United States, Australia, Austria, Canada, France, Greece, Indonesia, Italy, Philippines, Singapore, South Korea, Spain, Sweden, Switzerland, Thailand
Source: ClinicalTrials.gov record NCT00101608. Inclusion in this directory is not an endorsement.